Published in Cell Cycle on February 26, 2013
Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer. PLoS One (2014) 0.98
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget (2014) 0.98
Gene markers of cellular aging in human multipotent stromal cells in culture. Stem Cell Res Ther (2014) 0.97
The global landscape of intron retentions in lung adenocarcinoma. BMC Med Genomics (2014) 0.88
The role of EMMPRIN expression in ovarian epithelial carcinomas. Cell Cycle (2013) 0.87
Runx1 is associated with breast cancer progression in MMTV-PyMT transgenic mice and its depletion in vitro inhibits migration and invasion. J Cell Physiol (2015) 0.86
Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition. Oncotarget (2017) 0.82
Inhibition of RUNX2 transcriptional activity blocks the proliferation, migration and invasion of epithelial ovarian carcinoma cells. PLoS One (2013) 0.81
BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism. Oncotarget (2015) 0.79
Transient RUNX1 Expression during Early Mesendodermal Differentiation of hESCs Promotes Epithelial to Mesenchymal Transition through TGFB2 Signaling. Stem Cell Reports (2016) 0.78
RUNX1 and FOXP3 interplay regulates expression of breast cancer related genes. Oncotarget (2016) 0.78
MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells. Tumour Biol (2016) 0.77
The miR-101/RUNX1 feedback regulatory loop modulates chemo-sensitivity and invasion in human lung cancer. Int J Clin Exp Med (2015) 0.77
The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells. Oncotarget (2016) 0.77
Evolution, ovulation and cancer. Elife (2013) 0.76
Role of HCP5-miR-139-RUNX1 Feedback Loop in Regulating Malignant Behavior of Glioma Cells. Mol Ther (2016) 0.76
Splice variants of zinc finger protein 695 mRNA associated to ovarian cancer. J Ovarian Res (2013) 0.76
Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease. Genes Cancer (2015) 0.76
Computational analysis of the mesenchymal signature landscape in gliomas. BMC Med Genomics (2017) 0.75
Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells. Cell Cycle (2017) 0.75
Precocious Phenotypic Transcription-Factor Expression during Early Development. J Cell Biochem (2016) 0.75
Thyroid Hormone Receptor-β (TRβ) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid Cancer. Endocrinology (2016) 0.75
5-Azacytidine promotes invadopodia formation and tumor metastasis through the upregulation of PI3K in ovarian cancer cells. Oncotarget (2017) 0.75
miR-375 Regulates Invasion-Related Proteins Vimentin and L-Plastin. Am J Pathol (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
The epigenomics of cancer. Cell (2007) 30.91
AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell (1996) 9.74
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes. Nucleic Acids Res (2005) 4.52
CD34: structure, biology, and clinical utility. Blood (1996) 4.41
The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer (2005) 3.59
Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer (2002) 3.18
Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci (2008) 3.16
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest (2011) 2.32
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res (2012) 2.26
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst (2000) 1.99
Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem (2000) 1.98
Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics (2009) 1.91
Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res (2007) 1.90
Cancer epigenetics. Oncogene (2003) 1.80
The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med (2002) 1.75
Optimized anti-tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule. Blood (2011) 1.70
NF-kappa B-mediated repression of growth arrest- and DNA-damage-inducible proteins 45alpha and gamma is essential for cancer cell survival. Proc Natl Acad Sci U S A (2004) 1.66
Minireview: epigenetic changes in ovarian cancer. Endocrinology (2009) 1.49
Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer (2003) 1.35
Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling. Oncogene (2005) 1.27
Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer. EMBO J (2012) 1.25
Interplay of transcription factors in T-cell differentiation and function: the role of Runx. Immunology (2010) 1.23
Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem (2011) 1.21
RGD peptides released from beta ig-h3, a TGF-beta-induced cell-adhesive molecule, mediate apoptosis. Oncogene (2003) 1.19
MEIS and PBX homeobox proteins in ovarian cancer. Eur J Cancer (2007) 1.19
DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics (2008) 1.17
Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res (2004) 1.16
The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. EMBO Mol Med (2011) 1.16
RUNX1 and its understudied role in breast cancer. Cell Cycle (2011) 1.16
First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Rev Anticancer Ther (2010) 1.15
Normal and transforming functions of RUNX1: a perspective. J Cell Physiol (2006) 1.15
Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia (2003) 1.15
Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics (2008) 1.13
RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53. Oncogene (2004) 1.12
DNA demethylation and cancer: therapeutic implications. Cancer Lett (2004) 1.11
ATF3 regulates the stability of p53: a link to cancer. Cell Cycle (2006) 1.11
Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and riskof colon and rectal cancer: additional support for a TGF-β-signaling pathway. Carcinogenesis (2010) 1.11
Cyclin A1 is a p53-induced gene that mediates apoptosis, G2/M arrest, and mitotic catastrophe in renal, ovarian, and lung carcinoma cells. Cell Mol Life Sci (2006) 1.10
Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma. Cancer Res (2002) 1.10
Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells. Oncogene (2006) 1.10
Oncogenic pathways implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am (2003) 1.09
Dimethylbenzanthracene carcinogenesis in Gadd45a-null mice is associated with decreased DNA repair and increased mutation frequency. Cancer Res (2001) 1.08
The prodomain of interleukin 1alpha interacts with elements of the RNA processing apparatus and induces apoptosis in malignant cells. FASEB J (2003) 1.08
Inactivation of 14-3-3sigma influences telomere behavior and ionizing radiation-induced chromosomal instability. Mol Cell Biol (2000) 1.06
RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress. Oncogene (2009) 1.03
SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer. PLoS One (2012) 1.02
Identifying significant genetic regulatory networks in the prostate cancer from microarray data based on transcription factor analysis and conditional independency. BMC Med Genomics (2009) 1.02
Solution structure of core binding factor beta and map of the CBF alpha binding site. Nat Struct Biol (1999) 1.01
Cx43 suppresses mammary tumor metastasis to the lung in a Cx43 mutant mouse model of human disease. Oncogene (2010) 1.01
New mechanisms of AML1 gene alteration in hematological malignancies. Leukemia (2003) 1.01
New insights into the role of Runx1 in epithelial stem cell biology and pathology. J Cell Biochem (2013) 0.99
A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma. Cancer Res (2004) 0.99
Basic fibroblast growth factor confers a less malignant phenotype in MDA-MB-231 human breast cancer cells. Cancer Res (2000) 0.96
Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol Oncol (2011) 0.95
Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma. Hum Pathol (2010) 0.94
Overexpression of runt-related transcription factor-2 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. J Biomed Biotechnol (2012) 0.94
Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling. Cancer Res (2010) 0.94
Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice. Oncogene (2005) 0.94
Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype. Cell Cycle (2012) 0.94
Runx regulation of sphingolipid metabolism and survival signaling. Cancer Res (2010) 0.93
Abundance of cyclin B1 regulates gamma-radiation-induced apoptosis. Blood (2000) 0.93
RUNX3 interactome reveals novel centrosomal targeting of RUNX family of transcription factors. Cell Cycle (2012) 0.92
Runx family genes, niche, and stem cell quiescence. Blood Cells Mol Dis (2010) 0.92
Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles. Oncology (2011) 0.91
RUNX3 functions as an oncogene in ovarian cancer. Gynecol Oncol (2011) 0.91
TGF-β: friend or foe? The role of TGF-β/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy. Expert Opin Ther Targets (2010) 0.91
Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Int J Gynecol Pathol (2011) 0.91
The expression of decorin in human ovarian tumors. Clin Cancer Res (2002) 0.90
Identifying DNA methylation biomarkers of cancer drug response. Am J Pharmacogenomics (2005) 0.90
Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol (2008) 0.90
An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis. Int J Cancer (2009) 0.90
Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol (2011) 0.89
Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression. Gynecol Oncol (2012) 0.89
Runx1 is a tumor suppressor gene in the mouse gastrointestinal tract. Cancer Sci (2012) 0.87
Adrenomedullin in ovarian cancer: foe in vitro and friend in vivo? PLoS One (2012) 0.86
PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression. Carcinogenesis (2012) 0.83
Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol (2012) 0.83
Activating transcription factor 3 (ATF3) promotes sublytic C5b-9-induced glomerular mesangial cells apoptosis through up-regulation of Gadd45α and KLF6 gene expression. Immunobiology (2011) 0.83
SNAI1 overexpression induces stemness and promotes ovarian cancer cell invasion and metastasis. Oncol Rep (2012) 0.80
RNA interference using a plasmid construct expressing short-hairpin RNA. Methods Mol Biol (2007) 0.80
Id2 promotes the invasive growth of MCF-7 and SKOV-3 cells by a novel mechanism independent of dimerization to basic helix-loop-helix factors. BMC Cancer (2009) 0.80
RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines. OMICS (2009) 0.79
Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-alpha-peptide prodrugs. Cancer Res (2000) 0.78
Coexpression of calcitonin receptor-like receptor and receptor activity-modifying protein 2 or 3 mediates the antimigratory effect of adrenomedullin. Endocrinology (2003) 0.78
14-3-3sigma and p21 synergize to determine DNA damage response following Chk2 inhibition. Cell Cycle (2009) 0.78
MMPs in ovarian cancer as therapeutic targets. Anticancer Agents Med Chem (2012) 0.77
Murine models of ovarian cancer for preclinical testing of targeted therapeutics: has their time arrived? Cell Cycle (2012) 0.76
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol (2006) 4.92
Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol Oncol (2005) 2.62
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can (2007) 2.09
Vaginal radical trachelectomy: an oncologically safe fertility-preserving surgery. An updated series of 72 cases and review of the literature. Gynecol Oncol (2004) 1.85
Preoperative bowel preparation in gynecologic oncology: a review of practice patterns and an impetus to change. Int J Gynecol Cancer (2011) 1.39
The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies. Gynecol Oncol (2011) 1.38
Differential 1-year clinical outcomes for ST-segment elevation myocardial infarction related to stent thrombosis or saphenous vein graft thrombosis. Catheter Cardiovasc Interv (2013) 1.38
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol (2013) 1.36
YY1 is regulated by O-linked N-acetylglucosaminylation (O-glcNAcylation). J Biol Chem (2003) 1.25
Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res (2006) 1.23
Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab (2004) 1.19
Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. J Med Genet (2006) 1.17
Histone deacetylase (HDAC) activity is critical for embryonic kidney gene expression, growth, and differentiation. J Biol Chem (2011) 1.14
Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics (2008) 1.13
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol (2005) 1.13
Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol (2006) 1.11
Death receptor-3, a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Cancer Res (2006) 1.07
Laparoscopic sentinel node mapping in early-stage cervical cancer. Gynecol Oncol (2003) 1.05
No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result. Cancer Epidemiol Biomarkers Prev (2005) 1.04
First-line therapy in ovarian cancer trials. Int J Gynecol Cancer (2011) 1.03
Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle (2012) 1.01
Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol (2008) 1.00
Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. Int J Oncol (2006) 0.99
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat (2012) 0.98
Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer. Clin Cancer Res (2008) 0.98
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget (2014) 0.98
Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle (2010) 0.95
Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. Hum Genet (2005) 0.94
Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. J Clin Endocrinol Metab (2010) 0.93
The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res (2004) 0.92
Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. J Clin Endocrinol Metab (2010) 0.91
Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol (2008) 0.90
Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer (2006) 0.90
Bradykinin B2 receptor gene polymorphism is associated with altered urinary albumin/creatinine values in diabetic patients. Can J Physiol Pharmacol (2002) 0.90
Value of sentinel node mapping in cancer of the cervix. Gynecol Oncol (2011) 0.90
Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol (2011) 0.89
Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression. Gynecol Oncol (2012) 0.89
Initial evaluation and referral guidelines for management of pelvic/ovarian masses. J Obstet Gynaecol Can (2009) 0.88
Mixed ovarian large cell neuroendocrine carcinoma, mucinous adenocarcinoma, and teratoma: a report of two cases and review of the literature. Pathol Res Pract (2009) 0.87
Role of malignant ascites on human mesothelial cells and their gene expression profiles. BMC Cancer (2014) 0.87
Genes invoked in the ovarian transition to menopause. Nucleic Acids Res (2006) 0.86
Should ovaries be removed or not in (early-stage) adenocarcinoma of the uterine cervix: a review. Gynecol Oncol (2014) 0.86
Primary villoglandular adenocarcinoma of cloacogenic origin of the vulva. Hum Pathol (2004) 0.86
No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families. Genet Test (2006) 0.86
Molecular determinants of LPS-induced acute renal inflammation: Implication of the kinin B1 receptor. Biochem Biophys Res Commun (2009) 0.85
Mucinous ovarian tumors of Mullerian-type: an analysis of 17 cases including borderline tumors and intraepithelial, microinvasive, and invasive carcinomas. Int J Gynecol Pathol (2005) 0.85
Health behaviors and psychological distress in women initiating BRCA1/2 genetic testing: comparison with control population. J Genet Couns (2008) 0.85
Effect on bleeding, time to revascularization, and one-year clinical outcomes of the radial approach during primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol (2010) 0.85
Metastatic gastrointestinal tract cancer presenting as ovarian carcinoma. J Obstet Gynaecol Can (2003) 0.84
Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. PLoS One (2011) 0.84
SOGC–GOC–SCC Joint Policy Statement. No. 255, March 2011. Cervical cancer prevention in low-resource settings. J Obstet Gynaecol Can (2011) 0.84
Simple vaginal trachelectomy in early-stage low-risk cervical cancer: a pilot study of 16 cases and review of the literature. Int J Gynecol Cancer (2013) 0.84
Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population. Int J Gynecol Cancer (2012) 0.84
Ovarian thecoma associated with a large quantity of ascites and elevated serum CA 125 and CA 15-3. J Obstet Gynaecol Can (2002) 0.84
Genome-wide analysis of the p53 gene regulatory network in the developing mouse kidney. Physiol Genomics (2013) 0.83
Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec. Eur J Hum Genet (2011) 0.82
Sentinel lymph node biopsy in patients with gynecologic cancers Expert panel statement from the International Sentinel Node Society Meeting, February 21, 2008. Gynecol Oncol (2009) 0.82
Radical vaginal trachelectomy: a fertility-preserving option for young women with early stage cervical cancer. Gynecol Oncol (2005) 0.82
COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. OMICS (2011) 0.82
Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine. Mod Pathol (2013) 0.82
The role of adjuvant therapy in endometrial cancer. J Obstet Gynaecol Can (2013) 0.81
Primitive clear cell carcinoma of the vagina treated conservatively. J Obstet Gynaecol Can (2009) 0.81
Inhibition of RUNX2 transcriptional activity blocks the proliferation, migration and invasion of epithelial ovarian carcinoma cells. PLoS One (2013) 0.81
Specimen quality evaluation in Canadian biobanks participating in the COEUR repository. Biopreserv Biobank (2013) 0.81
Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Gynecol Oncol (2012) 0.81
The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures. Int J Biochem Cell Biol (2008) 0.81